Literature DB >> 7489233

Abnormal reverse cholesterol transport in controlled type II diabetic patients. Studies on fasting and postprandial LpA-I particles.

E Cavallero1, F Brites, B Delfly, N Nicolaïew, C Decossin, C De Geitere, J C Fruchart, R Wikinski, B Jacotot, G Castro.   

Abstract

The high incidence and prevalence of coronary heart disease in diabetes mellitus is clearly established. The usual lipid pattern found in type II diabetic patients is a moderate increase in fasting triglyceride levels associated with low HDL cholesterol levels. These abnormalities are further amplified in the postprandial state. To study the effect of these alterations on reverse cholesterol transport, we isolated lipoprotein containing apoA-I but not apoA-II (LpA-I) particles by immunoaffinity chromatography from the plasma of well-controlled type II diabetic patients and nondiabetic matched control subjects. Different parameters involved in this antiatherogenic pathway were measured in both fasting and postprandial states. Diabetic patients had reduced levels of LpA-I particles that were protein enriched and phospholipid depleted. Gradient gel electrophoresis showed that control LpA-I particles had five distinct populations, whereas diabetic particles lacked the largest one. LpA-I isolated from diabetic plasma exhibited a decreased capacity to induce cholesterol efflux from Ob 1771 adipose cells both in fasting (15.1 +/- 10.0% versus 7.5 +/- 2.7%, P < .05) and postprandial (17.7 +/- 11.2% versus 7.7 +/- 3.9%, P < .05) states, whereas only control particles showed significantly higher ability to promote cholesterol efflux after the test meal (P = .02). Lecithin:cholesterol acyltransferase activity measured with an exogenous substrate showed a 54% increase and an 18% decrease postprandially for control subjects and patients, respectively. Thus, the different abnormalities found in the fasting state were further amplified in the postprandial situation. This resulted in LpA-I particles with aberrant size and composition and decreased ability to accomplish their antiatherogenic role in type II diabetic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489233     DOI: 10.1161/01.atv.15.12.2130

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  14 in total

1.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

2.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 3.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

Review 4.  High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.

Authors:  Anand Rohatgi
Journal:  Prog Cardiovasc Dis       Date:  2015-05-09       Impact factor: 8.194

5.  Triacylglycerol-rich lipoproteins alter the secretion, and the cholesterol-effluxing function, of apolipoprotein E-containing lipoprotein particles from human (THP-1) macrophages.

Authors:  E M Lindholm; A M Palmer; A Graham
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

Review 6.  Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases.

Authors:  Parth N Patel; Rhia Y Shah; Jane F Ferguson; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12-30       Impact factor: 8.311

7.  Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.

Authors:  Quang Huy Lê; Meddy El Alaoui; Evelyne Véricel; Bérénice Ségrestin; Laurent Soulère; Michel Guichardant; Michel Lagarde; Philippe Moulin; Catherine Calzada
Journal:  J Clin Endocrinol Metab       Date:  2015-03-20       Impact factor: 5.958

Review 8.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

Review 9.  Why is HDL functionally deficient in type 2 diabetes?

Authors:  Anatol Kontush; M John Chapman
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

10.  Influence of fasting status on the effects of coconut oil on chick plasma and lipoprotein composition.

Authors:  E García-Fuentes; A Gil-Villarino; M F Zafra; E García-Peregrín
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.